Cognition Therapeutics (CGTX) News Today → Everybody laughed when he recommended Netflix (From Stansberry Research) (Ad) Free CGTX Stock Alerts $1.98 +0.02 (+1.02%) (As of 12:25 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 7, 2024 | finanznachrichten.deCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateMay 7, 2024 | globenewswire.comCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateApril 29, 2024 | finance.yahoo.comCognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy BodiesApril 27, 2024 | marketbeat.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest UpdateCognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 220,300 shares, a growth of 46.7% from the March 31st total of 150,200 shares. Based on an average trading volume of 200,700 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.7% of the shares of the company are short sold.April 22, 2024 | finance.yahoo.comCognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s DiseaseApril 12, 2024 | marketbeat.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Drop in Short InterestCognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 150,200 shares, a decline of 34.2% from the March 15th total of 228,100 shares. Based on an average trading volume of 204,700 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.5% of the company's shares are sold short.April 2, 2024 | globenewswire.comCognition Therapeutics to Present at the Needham Virtual Healthcare ConferenceApril 1, 2024 | finance.yahoo.comCognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024April 1, 2024 | globenewswire.comCognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024March 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical TrialsMarch 28, 2024 | marketbeat.comB. Riley Reiterates "Buy" Rating for Cognition Therapeutics (NASDAQ:CGTX)B. Riley reissued a "buy" rating and set a $5.00 price target on shares of Cognition Therapeutics in a research report on Thursday.March 27, 2024 | finance.yahoo.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | marketbeat.comCognition Therapeutics (NASDAQ:CGTX) Rating Reiterated by OppenheimerOppenheimer reaffirmed an "outperform" rating and issued a $9.00 price target on shares of Cognition Therapeutics in a research note on Wednesday.March 26, 2024 | globenewswire.comCognition Therapeutics Reports Year End 2023 Financial Results and Provides Business UpdateMarch 26, 2024 | benzinga.comA Preview Of Cognition Therapeutics's EarningsMarch 15, 2024 | marketbeat.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Significant Increase in Short InterestCognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) saw a significant increase in short interest in the month of February. As of February 29th, there was short interest totalling 126,800 shares, an increase of 26.2% from the February 14th total of 100,500 shares. Based on an average trading volume of 234,900 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.6% of the company's shares are sold short.March 15, 2024 | globenewswire.comCognition Therapeutics to Report Fourth Quarter and Full Year 2023 ResultsMarch 14, 2024 | globenewswire.comCognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common StockMarch 12, 2024 | markets.businessinsider.comCognition Therapeutics Prices Public Offering Of About 6.57 Mln Shares At $1.75/shrMarch 12, 2024 | msn.comCognition Therapeutics announces pricing of stock offering to raise $11.5MMarch 11, 2024 | msn.comGiants GM Joe Schoen swings big in trade, blockbuster contract for Panthers pass rusher Brian Burns while losing Xavier McKinneyMarch 11, 2024 | globenewswire.comCognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common StockMarch 11, 2024 | globenewswire.comCognition Therapeutics Announces Proposed Public Offering of Common StockMarch 6, 2024 | finance.yahoo.comCognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease StudiesMarch 6, 2024 | globenewswire.comCognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease StudiesFebruary 26, 2024 | globenewswire.comCognition Therapeutics to Present at the TD Cowen Health Care ConferenceFebruary 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)February 6, 2024 | finanznachrichten.deCognition Therapeutics, Inc.: New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812February 6, 2024 | finance.yahoo.comNew Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812February 1, 2024 | msn.comStudy suggests how cognitive behavioral therapy changes brain activity in children with anxietyJanuary 16, 2024 | finance.yahoo.comHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn SituationJanuary 8, 2024 | msn.comDigital CBT intervention reduces anxiety and improves quality of life for pulmonary fibrosis patientsJanuary 4, 2024 | finanznachrichten.deCognition Therapeutics, Inc.: Cognition Therapeutics CEO Issues Letter to ShareholdersJanuary 4, 2024 | finance.yahoo.comCognition Therapeutics CEO Issues Letter to ShareholdersDecember 29, 2023 | msn.comCognition Therapeutics files to sell 6.03M shares for holdersNovember 22, 2023 | morningstar.comCognition Therapeutics Inc CGTXNovember 16, 2023 | finance.yahoo.comCognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensNovember 15, 2023 | stockhouse.comCognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's DiseasesNovember 15, 2023 | finance.yahoo.comCognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s DiseasesNovember 7, 2023 | benzinga.comCognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseNovember 7, 2023 | finance.yahoo.comCognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseNovember 3, 2023 | finance.yahoo.comCognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial ResultsNovember 2, 2023 | msn.comCognition Therapeutics GAAP EPS of $0.22 beats by $0.46November 2, 2023 | finance.yahoo.comCognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 27, 2023 | finance.yahoo.comCognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTADOctober 24, 2023 | stockhouse.comCognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTADOctober 24, 2023 | finance.yahoo.comCognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTADOctober 16, 2023 | finance.yahoo.comCognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS IndicationsSeptember 27, 2023 | thestreet.comCognition Therapeutics Inc. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… CGTX Media Mentions By Week CGTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGTX News Sentiment▼0.000.42▲Average Medical News Sentiment CGTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGTX Articles This Week▼01▲CGTX Articles Average Week Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Precision BioSciences News Today Elutia News Today Instil Bio News Today Gritstone bio News Today CEL-SCI News Today SCYNEXIS News Today Athira Pharma News Today Protalix BioTherapeutics News Today Atara Biotherapeutics News Today Entera Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGTX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
